Tarlatamab + durvalumab poised to become 1L maintenance SoC in ES-SCLC

12 Nov 2026
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
Dr Jacob SandsDr Jacob Sands

Adding tarlatamab to first-line (1L) durvalumab maintenance therapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs durvalumab alone in patients with extensive-stage small-cell lung cancer (ES-SCLC), results of the phase III DeLLphi-305 trial have shown.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 on cancer cells and CD3 on T cells. “DeLLphi-305 outcomes support tarlatamab plus durvalumab as a new standard-of-care [SoC] 1L maintenance therapy in ES-SCLC,” said investigator Dr Jacob Sands of Dana-Farber Cancer Institute, Boston, Massachusetts, US, at ESMO 2026. [Sands J, et al, ESMO 2026, abstract LBA3; N Engl J Med 2026;doi:10.1056/NEJMoa2609482]

In the open-label multicentre trial, 563 patients with ES-SCLC without progression after 1L platinum and etoposide plus durvalumab were randomized 1:1 to receive maintenance therapy with tarlatamab (10 mg Q2W) plus durvalumab (1,500 mg Q4W) (n=282; median age, 65 years; male, 69.9 percent; from Asia-Pacific, 40.4 percent) or durvalumab alone (n=281; median age, 65 years; male, 71.5 percent; from Asia-Pacific, 35.9 percent) until disease progression or unacceptable toxicity.

At baseline, a meaningful proportion of patients had current or prior brain metastasis (19.5 vs 19.9 percent in the tarlatamab + durvalumab vs durvalumab group) or liver metastasis (31.2 vs 33.8 percent).

Unprecedented survival gains

Tarlatamab + durvalumab significantly improved the primary endpoint of OS vs durvalumab alone. Median OS was 21.1 vs 12.7 months (hazard ratio [HR], 0.42; 95 percent confidence interval [CI], 0.32–0.54; p<0.001), after a median follow-up of 15.9 and 16.1 months in the respective groups. OS rates at 6 and 12 months were 91.5 vs 74.6 percent and 79.4 vs 53.3 percent, respectively.

Median PFS (key secondary endpoint) was also significantly improved with tarlatamab + durvalumab vs durvalumab alone (7.4 vs 1.9 months; HR, 0.34; 95 percent CI, 0.28–0.42; p<0.001), after a median follow-up of 13.9 months in each group. PFS rates at 6 and 12 months were 53.4 vs 17.2 percent and 38.4 vs 9.5 percent, respectively.

“OS and PFS benefits were consistent across all key prespecified subgroups, including in patients with or without brain or liver metastasis at baseline, and regardless of response to initial therapy,” reported Sands.

“DeLLphi-305 showed real signs of durable benefit by adding tarlatamab to 1L maintenance durvalumab in ES-SCLC. The survival gains are of a magnitude not previously seen in SCLC,” said discussant Dr Stephen Liu of Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, US.

Improved ORR

ORR was significantly higher with tarlatamab + durvalumab vs durvalumab alone, at 26.4 vs 4.1 percent (p<0.001). Median duration of response was 12.7 vs 5.6 months.

“Among patients with a response to tarlatamab plus durvalumab maintenance, 52 percent continued to have that response at 1 year,” Sands noted. “At data cut-off, 43.6 and 11.4 percent of patients in the respective groups remained on treatment.”

Manageable safety profile

“Tarlatamab plus durvalumab demonstrated a manageable safety profile consistent with the individual agents, with low rates of treatment discontinuation due to adverse events [AEs],” said Sands.

Grade ≥3 treatment-emergent AEs (TEAEs) were reported in 46.8 vs 40.6 percent of patients in the tarlatamab + durvalumab vs durvalumab group, while grade ≥3 treatment-related AEs (TRAEs) occurred in 20.9 vs 10.8 percent. These AEs led to treatment discontinuation in 3.2–5.7 vs 3.6–5.8 percent of patients.

Cytokine release syndrome (CRS) and immune-effector cell–associated neurotoxicity syndrome (ICANS) occurred in 49.6 vs 1.4 percent and 1.1 vs 0 percent of patients, respectively, but were mostly of low grade (grade ≥3 CRS, 0.4 vs 0 percent; no grade ≥3 ICANS), with no fatal events.